The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting

Derek T. Hall, Takla Griss, Jennifer F. Ma, Brenda Janice Sanchez, Jason Sadek, Anne Marie K. Tremblay, Souad Mubaid, Amr Omer, Rebecca J. Ford, Nathalie Bedard, Arnim Pause, Simon S. Wing, Sergio Di Marco, Gregory R. Steinberg, Russell G. Jones, Imed Gallouzi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Activation of AMPK has been associated with pro-atrophic signaling in muscle. However, AMPK also has anti-inflammatory effects, suggesting that in cachexia, a syndrome of inflammatory-driven muscle wasting, AMPK activation could be beneficial. Here we show that the AMPK agonist AICAR suppresses IFNγ/TNFα-induced atrophy, while the mitochondrial inhibitor metformin does not. IFNγ/TNFα impair mitochondrial oxidative respiration in myotubes and promote a metabolic shift to aerobic glycolysis, similarly to metformin. In contrast, AICAR partially restored metabolic function. The effects of AICAR were prevented by the AMPK inhibitor Compound C and were reproduced with A-769662, a specific AMPK activator. AICAR and A-769662 co-treatment was found to be synergistic, suggesting that the anti-cachectic effects of these drugs are mediated through AMPK activation. AICAR spared muscle mass in mouse models of cancer and LPS induced atrophy. Together, our findings suggest a dual function for AMPK during inflammation-driven atrophy, wherein it can play a protective role when activated exogenously early in disease progression, but may contribute to anabolic suppression and atrophy when activated later through mitochondrial dysfunction and subsequent metabolic stress.

Original languageEnglish
JournalEMBO Molecular Medicine
DOIs
Publication statusAccepted/In press - 1 Jan 2018

Fingerprint

AMP-Activated Protein Kinases
Metformin
Inflammation
Muscles
A 769662
Atrophy
Cachexia
Physiological Stress
AICA ribonucleotide
4-aminoimidazole
Skeletal Muscle Fibers
Glycolysis
Disease Progression
Respiration
Anti-Inflammatory Agents

Keywords

  • AMPK
  • Cachexia
  • Inflammation
  • iNOS
  • Metabolism

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting. / Hall, Derek T.; Griss, Takla; Ma, Jennifer F.; Sanchez, Brenda Janice; Sadek, Jason; Tremblay, Anne Marie K.; Mubaid, Souad; Omer, Amr; Ford, Rebecca J.; Bedard, Nathalie; Pause, Arnim; Wing, Simon S.; Di Marco, Sergio; Steinberg, Gregory R.; Jones, Russell G.; Gallouzi, Imed.

In: EMBO Molecular Medicine, 01.01.2018.

Research output: Contribution to journalArticle

Hall, DT, Griss, T, Ma, JF, Sanchez, BJ, Sadek, J, Tremblay, AMK, Mubaid, S, Omer, A, Ford, RJ, Bedard, N, Pause, A, Wing, SS, Di Marco, S, Steinberg, GR, Jones, RG & Gallouzi, I 2018, 'The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting', EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201708307
Hall, Derek T. ; Griss, Takla ; Ma, Jennifer F. ; Sanchez, Brenda Janice ; Sadek, Jason ; Tremblay, Anne Marie K. ; Mubaid, Souad ; Omer, Amr ; Ford, Rebecca J. ; Bedard, Nathalie ; Pause, Arnim ; Wing, Simon S. ; Di Marco, Sergio ; Steinberg, Gregory R. ; Jones, Russell G. ; Gallouzi, Imed. / The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting. In: EMBO Molecular Medicine. 2018.
@article{0d08b29ea95c48d09809b29961268d3a,
title = "The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting",
abstract = "Activation of AMPK has been associated with pro-atrophic signaling in muscle. However, AMPK also has anti-inflammatory effects, suggesting that in cachexia, a syndrome of inflammatory-driven muscle wasting, AMPK activation could be beneficial. Here we show that the AMPK agonist AICAR suppresses IFNγ/TNFα-induced atrophy, while the mitochondrial inhibitor metformin does not. IFNγ/TNFα impair mitochondrial oxidative respiration in myotubes and promote a metabolic shift to aerobic glycolysis, similarly to metformin. In contrast, AICAR partially restored metabolic function. The effects of AICAR were prevented by the AMPK inhibitor Compound C and were reproduced with A-769662, a specific AMPK activator. AICAR and A-769662 co-treatment was found to be synergistic, suggesting that the anti-cachectic effects of these drugs are mediated through AMPK activation. AICAR spared muscle mass in mouse models of cancer and LPS induced atrophy. Together, our findings suggest a dual function for AMPK during inflammation-driven atrophy, wherein it can play a protective role when activated exogenously early in disease progression, but may contribute to anabolic suppression and atrophy when activated later through mitochondrial dysfunction and subsequent metabolic stress.",
keywords = "AMPK, Cachexia, Inflammation, iNOS, Metabolism",
author = "Hall, {Derek T.} and Takla Griss and Ma, {Jennifer F.} and Sanchez, {Brenda Janice} and Jason Sadek and Tremblay, {Anne Marie K.} and Souad Mubaid and Amr Omer and Ford, {Rebecca J.} and Nathalie Bedard and Arnim Pause and Wing, {Simon S.} and {Di Marco}, Sergio and Steinberg, {Gregory R.} and Jones, {Russell G.} and Imed Gallouzi",
year = "2018",
month = "1",
day = "1",
doi = "10.15252/emmm.201708307",
language = "English",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting

AU - Hall, Derek T.

AU - Griss, Takla

AU - Ma, Jennifer F.

AU - Sanchez, Brenda Janice

AU - Sadek, Jason

AU - Tremblay, Anne Marie K.

AU - Mubaid, Souad

AU - Omer, Amr

AU - Ford, Rebecca J.

AU - Bedard, Nathalie

AU - Pause, Arnim

AU - Wing, Simon S.

AU - Di Marco, Sergio

AU - Steinberg, Gregory R.

AU - Jones, Russell G.

AU - Gallouzi, Imed

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Activation of AMPK has been associated with pro-atrophic signaling in muscle. However, AMPK also has anti-inflammatory effects, suggesting that in cachexia, a syndrome of inflammatory-driven muscle wasting, AMPK activation could be beneficial. Here we show that the AMPK agonist AICAR suppresses IFNγ/TNFα-induced atrophy, while the mitochondrial inhibitor metformin does not. IFNγ/TNFα impair mitochondrial oxidative respiration in myotubes and promote a metabolic shift to aerobic glycolysis, similarly to metformin. In contrast, AICAR partially restored metabolic function. The effects of AICAR were prevented by the AMPK inhibitor Compound C and were reproduced with A-769662, a specific AMPK activator. AICAR and A-769662 co-treatment was found to be synergistic, suggesting that the anti-cachectic effects of these drugs are mediated through AMPK activation. AICAR spared muscle mass in mouse models of cancer and LPS induced atrophy. Together, our findings suggest a dual function for AMPK during inflammation-driven atrophy, wherein it can play a protective role when activated exogenously early in disease progression, but may contribute to anabolic suppression and atrophy when activated later through mitochondrial dysfunction and subsequent metabolic stress.

AB - Activation of AMPK has been associated with pro-atrophic signaling in muscle. However, AMPK also has anti-inflammatory effects, suggesting that in cachexia, a syndrome of inflammatory-driven muscle wasting, AMPK activation could be beneficial. Here we show that the AMPK agonist AICAR suppresses IFNγ/TNFα-induced atrophy, while the mitochondrial inhibitor metformin does not. IFNγ/TNFα impair mitochondrial oxidative respiration in myotubes and promote a metabolic shift to aerobic glycolysis, similarly to metformin. In contrast, AICAR partially restored metabolic function. The effects of AICAR were prevented by the AMPK inhibitor Compound C and were reproduced with A-769662, a specific AMPK activator. AICAR and A-769662 co-treatment was found to be synergistic, suggesting that the anti-cachectic effects of these drugs are mediated through AMPK activation. AICAR spared muscle mass in mouse models of cancer and LPS induced atrophy. Together, our findings suggest a dual function for AMPK during inflammation-driven atrophy, wherein it can play a protective role when activated exogenously early in disease progression, but may contribute to anabolic suppression and atrophy when activated later through mitochondrial dysfunction and subsequent metabolic stress.

KW - AMPK

KW - Cachexia

KW - Inflammation

KW - iNOS

KW - Metabolism

UR - http://www.scopus.com/inward/record.url?scp=85047741700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047741700&partnerID=8YFLogxK

U2 - 10.15252/emmm.201708307

DO - 10.15252/emmm.201708307

M3 - Article

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

ER -